Standout Papers

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refr... 1998 2026 2007 2016 707
  1. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. (1998)
    Corinne Haïoun, Nicolas Ketterer et al. Blood

Immediate Impact

3 by Nobel laureates 17 from Science/Nature 58 standout
Sub-graph 1 of 20

Citing Papers

Harnessing innate immunity in cancer therapy
2019 StandoutNature
Spermidine in health and disease
2018 StandoutScience
2 intermediate papers

Works of H Tilly being referenced

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
1998 Standout

Author Peers

Author Last Decade Papers Cites
H Tilly 1274 665 454 846 44 2.0k
R. E. Marcus 1080 622 509 967 47 1.9k
Joke W. Baars 880 494 635 923 52 2.3k
J. O. Armitage 1397 596 581 1063 52 2.4k
Paolo G. Gobbi 1533 657 422 892 85 2.6k
Henry E. Wilson 1083 498 405 1013 45 2.2k
Anne Sonet 1271 567 259 848 63 2.1k
G. Lepeu 1202 646 236 761 27 1.6k
Christophe Fruchart 901 349 393 596 49 1.4k
Nicola Di Renzo 929 613 514 671 96 1.8k
Mathias Hänel 793 471 723 657 72 1.8k

All Works

Loading papers...

Rankless by CCL
2026